Top entities: EpiWatch, United States — Food and Drug Administration, Apple Inc., James W. Wheless, American Academy of Neurology.

What category does this event fall under?

Tech — classified as medical breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

United States — Food and Drug Administration cleared app EpiWatch · EpiWatch developed app · EpiWatch funded clinical trial

Is this event still developing?

This is an active story, last updated Jun 04, 2026. Coverage continues to evolve.

Tech medical breakthrough

EpiWatch App Detects Seizures Accurately

Q: When did this event occur?

First reported May 27, 2026; last updated Jun 04, 2026.

Q: What is the market impact?

Direct. The successful Phase III trial and FDA clearance of the EpiWatch app, which runs on the Apple Inc.

Analysis based on 8 articles · First reported May 27, 2026 · Last updated Jun 04, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The successful Phase III trial and FDA clearance of the EpiWatch app, which runs on the Apple Inc., is expected to positively impact the medical device and technology sectors. This innovation could lead to increased demand for smartwatches with advanced health monitoring capabilities and open new revenue streams for companies like EpiWatch.

Healthcare Technology Medical Devices

Event Summary

A new study published in Neurology Open Access, an official journal of the American Academy of Neurology, found that the EpiWatch smartwatch app accurately detected tonic-clonic seizures with a low rate of false alarms. The study, led in part by James W. Wheless of Le Bonheur Children s Hospital, involved 242 adults and children with epilepsy monitored in a hospital setting. The app detected 46 out of 47 tonic-clonic seizures, achieving a 98% sensitivity, and had a false alarm rate 90% lower than other devices. The United States — Food and Drug Administration has cleared the EpiWatch app for marketing. This development, which utilizes the Apple Inc. platform, is significant for improving epilepsy management, reducing the risk of sudden unexpected death in epilepsy (SUDEP), and encouraging consistent use due to its discreet nature.

Key Actions

95 United States — Food and Drug Administration cleared app EpiWatch

90 EpiWatch developed app

85 EpiWatch funded clinical trial

70 American Academy of Neurology published findings

Entities Involved

oth

EpiWatch

EpiWatch developed the EpiWatch app, which has shown high accuracy in detecting tonic-clonic seizures, leading to its FDA clearance and potential for widespread adoption. This event significantly boosts the company's market position and product credibility.

Importance 100 Sentiment 80

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration cleared the EpiWatch app for marketing, providing regulatory approval that validates its safety and effectiveness. This clearance is crucial for the app's commercialization and adoption in healthcare.

Importance 80 Sentiment 50

stock

Apple Inc.

The EpiWatch app operates on the Apple Inc., enhancing the device's utility and potentially increasing its market appeal to individuals with epilepsy and their caregivers. This expands the use cases for the Apple Inc. beyond general fitness and communication.

Importance 70 Sentiment 30

per

James W. Wheless

James W. Wheless is a study author and director at Le Bonheur Children s Hospital, providing expert commentary and leadership in the research of the EpiWatch app. His involvement lends significant medical authority to the study's findings.

Importance 70 Sentiment 60

ngo

American Academy of Neurology

The American Academy of Neurology published the study in its journal, Neurology Open Access, and endorses advances that improve diagnostic accuracy and patient quality of life. This provides scientific credibility and dissemination for the EpiWatch app's findings.

Importance 60 Sentiment 40

oth

Le Bonheur Children s Hospital

Le Bonheur Children s Hospital is where James W. Wheless works and contributed to the study, highlighting its role in advanced medical research and epilepsy care.

Importance 50 Sentiment 40

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard